Get the Stockscreener App
11.99
5.74%
-0.73
Gh Research Plc stock is traded at $11.99, with a volume of 105.53K.
It is down -5.74% in the last 24 hours and up +9.20% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$12.72
Open:
$12.71
24h Volume:
105.53K
Relative Volume:
0.58
Market Cap:
$796.44M
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-15.18
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
-6.62%
1M Performance:
+9.20%
6M Performance:
+41.73%
1Y Performance:
-3.31%
1-Day Range:
$11.90
$12.75
1-Week Range:
$11.90
$14.25
52-Week Range:
$6.00
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
11.99 | 796.44M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
J Sainsbury plc (OTCMKTS:JSAIY) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Millennium Management LLC Acquires Shares of 20,761 GH Research PLC (NASDAQ:GHRS) - Defense World
GH Research to Participate in Neuro Perspectives Conference - TipRanks
Two Sigma Investments LP Makes New Investment in GH Research PLC (NASDAQ:GHRS) - Defense World
Cantor Fitzgerald Weighs in on GH Research FY2026 Earnings - Defense World
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) With Overweight Rating - Insider Monkey
GH Research (NASDAQ:GHRS) Now Covered by Cantor Fitzgerald - Defense World
GHRS Stock Coverage Initiated with Positive Outlook | GHRS Stock News - GuruFocus
cantor fitzgerald maintains overweight rating on gh research stock By Investing.com - Investing.com Canada
cantor fitzgerald maintains overweight rating on gh research stock - Investing.com Australia
BNP Paribas Financial Markets Takes $44,000 Position in GH Research PLC (NASDAQ:GHRS) - Defense World
How To Trade (GHRS) - news.stocktradersdaily.com
Northern Trust Corp Has $286,000 Holdings in GH Research PLC (NASDAQ:GHRS) - Defense World
GH Research to Present at ASCP Meeting on Breakthrough Depression Treatment - TipRanks
(GHRS) Long Term Investment Analysis - news.stocktradersdaily.com
GH Research to Present at ASCP Meeting on Depression Treatments - TipRanks
GH Research PLC (NASDAQ:GHRS) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Beckley’s psychedelic reduces depression - BioWorld MedTech
GH Research (NASDAQ:GHRS) Upgraded at Cantor Fitzgerald - Defense World
GH Research (GHRS) Highlights Phase 2b Results at Clinical Confe - GuruFocus
GH Research (GHRS) Highlights Phase 2b Results at Clinical Conference | GHRS Stock News - GuruFocus
GH Research Showcases Promising Depression Treatment Data at ASCP Meeting - TipRanks
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting - Yahoo
GH Research’s (GHRS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Guggenheim Cuts GH Research (NASDAQ:GHRS) Price Target to $29.00 - Defense World
GH Research (GHRS) Price Target Lowered by Guggenheim | GHRS Sto - GuruFocus
GHRS Stock: HC Wainwright & Co. Reiterates Buy Rating | GHRS Sto - GuruFocus
GH Research: Promising Clinical Results and Strong Financial Position Justify Buy Rating - TipRanks
GH Research (GHRS) Price Target Lowered by Guggenheim | GHRS Stock News - GuruFocus
Psychedelic: Compass, GH Research, MindMed report quarterly earnings - Yahoo Finance
GH Research PLC Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
GHRS Reports Strong Financial Position with Increased Cash Holdi - GuruFocus
GH Research Reports Q1 2025 Financial Results Amidst Ongoing Challenges - TipRanks
GH Research PLC Reports Positive Phase 2b Trial Results for GH001 in Treatment-Resistant Depression and Financial Update for Q1 2025 - Nasdaq
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
What Makes GH Research (GHRS) a New Buy Stock - Yahoo Finance
Where are the Opportunities in (GHRS) - news.stocktradersdaily.com
Hims & Hers Health (NYSE:HIMS) Shares Down 8.3% Following Insider Selling - American Banking and Market News
Legal & General Group Plc Sells 18,302 Shares of Guardant Health, Inc. (NASDAQ:GH) - Defense World
What Will GH Research PLC (NASDAQ: GHRS) Be Like In 2025 - Stocksregister
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine
(GHRS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
(GHRS) Proactive Strategies - news.stocktradersdaily.com
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Guggenheim starts GH Research at Buy, sees long-term upside potential - Yahoo Finance
Guggenheim Initiates Coverage of GH Research (GHRS) with Buy Recommendation - Nasdaq
GH Research PLC (GHRS) Shares Rise Despite Market Challenges - The News Heater
How to Take Advantage of moves in (GHRS) - news.stocktradersdaily.com
GH Research (NASDAQ:GHRS) Earns Outperform Rating from Analysts at Royal Bank of Canada - Defense World
GH Research PLC (NASDAQ:GHRS) Receives $30.67 Consensus PT from Brokerages - Defense World
Q1 Earnings Forecast for GH Research Issued By HC Wainwright - Defense World
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):